To study acquired resistance formation to MDM2 inhibitors in AML cells, we here 90 established and analysed a panel of sub-lines of the TP53 wild-type AML cell lines 91 MV4-11, OCI-AML-2, OCI-AML-3, and SIG-M5, with acquired resistance to the MDM2 92 inhibitor nutlin-3 [3, 42] . In total, this included 45 nutlin-3-adapted sub-lines (15 MV4-93 11 sub-lines, 10 OCI-AML-2 sub-lines, 12 OCI-AML-3 sub-lines, 8 SIG-M5 sub-lines). 94 95 9 to screen for SNPs and InDels separately, using a low-stringency setting with minimal 145 variant frequency of 0.1, a minimum coverage of 20 and a minimum of 10 supporting 146 reads per variant to account for cellular and clonal heterogeneity. Minimum average 147 quality was set to 20 and a strand filter was applied to minimize miscalls due to poor 148 sequencing quality or amplification bias. The resulting list of putative variants was 149 compared against the IARC TP53 (R17) database to check for known p53 cancer 150 mutations. 151
Statistics 152
Results are expressed as mean ± S.D. of at least three experiments. 153
Comparisons between two groups were performed using Student's t-test. Three and 154 more groups were compared by ANOVA followed by the Student-Newman-Keuls test. 155 P values lower than 0.05 were considered to be significant. 156
Results 158
Nutlin-3 sensitivity/ resistance status of the nutlin-3-adapted AML sub-lines 159
To study acquired resistance formation to MDM2 inhibitors in AML cells, we 160 established and analysed a panel of sub-lines of the TP53 wild-type AML cell lines 161 MV4-11, OCI-AML-2, OCI-AML-3, and SIG-M5, with acquired resistance to the MDM2 162 inhibitor nutlin-3. The parental cell lines MV4-11, OCI-AML-2, OCI-AML-3, and SIG-163 M5 displayed sensitivity to nutlin-3 in a range of 0.90 to 2.33µM (Suppl. Table 1 ). The 164 nutlin-3 IC50 values in the nutlin-3-adapted sub-lines of 2.33µM) ranged from 13.3 to 22.6µM resulting in resistance factors (fold change nutlin-166 3 IC50 in nutlin-3-adapted MV4-11 sub-lines/ nutlin-3 IC50 in MV4-11) ranging 167 between 5.7 (MV4-11 r Nutlin 20µM XII) and 9.7 (MV4-11 r Nutlin 20µM II) (Figure 1 , Suppl. 168 Table 1) . 169
In the nutlin-3 adapted sub-lines of OCI-AML-2 (nutlin-3 IC50: 0.90µM), the 170 nutlin-3 IC50s ranged from 14.8µM (OCI-AML-2 r Nutlin 20µM XI, resistance factor: 16.4) 171 to 19.9µM (OCI-AML-2 r Nutlin 20µM II, resistance factor: 22.1) (Figure 2 , Suppl. Table 1) . 172
In the OCI-AML-3 (nutlin-3 IC50: 1.75µM) sub-lines, the nutlin-3 IC50s ranged from 173 11.3µM r Nutlin 20µM XII, resistance factor: 6.5) to 20.62µM (OCI-AML-174 3 r Nutlin 20µM XI, resistance factor 11.8) (Figure 3 , Suppl. Table 1 ) and in the SIG-M5 175 (Nutlin-3 IC50: 1.27µM) sub-lines from 3.64µM r Nutlin 20µM XV, resistance 176 factor: 2.9) to 23.5µM r Nutlin 20µM XI, resistance factor: 18.5) (Figure 4 , Suppl. 177 Table 1 ). 178
TP53 status of nutlin-3-adapted AML cell lines and nutlin-3 resistance 180
The determination of the TP53 status in the nutlin-3-adapted AML sub-lines 181 revealed that all MV4-11 sub-lines harboured the same heterozygous R248W mutation 182
and that all OCI-AML-2 sub-lines harboured the same heterozygous Y220C mutation 183 (Table 1 ). In contrast, the OCI-AML-3 and SIG-M5 sub-lines harboured a range of 184 different TP53 mutations and included sub-lines that had retained wild-type TP53. 185 (Table 1 ). In concordance, 219 out of 12418 reads of the appropriate TP53 region in 186 the parental MV4-11 cell line indicated the presence of alleles with an R248W mutation 187 and 98 out of 907 reads indicated the presence of alleles with a Y220C mutation in the 188 parental OCI-AML-2 cell line. In contrast, the mutations detected in the nutlin-3-189 adapted OCI-AML-3-and SIG-M5-sub-lines could not be detected in the respective 190 parental cell lines. Also, MV4-11 and OCI-AML-2 could be adapted to nutlin-3 in 12-15 191 passages, whereas the nutlin-3 adaptation of OCI-AML-3 and SIG-M5 required 30-35 192 passages. This indicates that MV4-11 and OCI-AML-2 contain pre-existing TP53-193 mutant subpopulation that are selected by nutlin-3 treatment, while nutlin-3 treatment 194 resulted in de novo TP53 mutations in OCI-AML-3 and SIG-M5. These results are 195 consistent with those obtained from other cancer entities [35, 36, 39, 41] . 196
Most of the TP53 mutations are in the DNA binding domain (aa 102-292). The 197 R248W mutation in the nutlin-3-adapted MV4-11 sub-lines and the Y220C mutation in 198 the nutlin-3-adapted OCI-AML-2 sub-lines belong to the ten most commonly mutated 199 TP53 positions. 12 of the further 13 mutations are also located in the DNA binding 200 domain and are known or expected to affect p53 function. Codon 27 is located in the 201 transactivation domain, which is relevant for the MDM2-p53 interaction. The P27S 202 mutation is known to increase the binding affinity of p53 to MDM2 [50] [51] [52] [53] . 203
There was no obvious relationship between the nutlin-3 IC50 in the parental cell 204 lines in which nutlin-3 selected pre-existing TP53-mutant subpopulations (MV4-11: 205 2.33µM, OCI-AML-2: 0.90µM) and those parental cell lines in which nutlin-3 induced 206 de novo TP53-mutations (OCI-AML-3: 1.75µM, SIG-M5: 1.27µM). The nutlin-3-207 adapted sub-lines displayed similar nutlin-3 IC50s independently of the mechanism of 208 resistance formation or nutlin-3 sensitivity of the respective parental cell line (Figure  209 5). The fold changes (nutlin-3 IC50 resistant sub-line/ nutlin-3 IC50 respective parental 210 cell line) were typically higher in parental cell lines that displayed lower nutlin-3 IC50 211 values ( Figure 5 ). In the OCI-AML-3-and SIG-M5-sub-lines, there was no significant 212 difference between the nutlin-3 IC50s in the TP53-mutant and TP53 wild-type cell lines 213 ( Figure 5 ). 214
Cross-resistance profiles in the nutlin-3-adapted AML sub-lines 215 Next, we determined sensitivity profiles of the nutlin-3-adapted AML sub-lines 216 to doxorubicin, etoposide, gemcitabine, cytarabine, and fludarabine ( Figure 1-4 , Suppl. 217 Table 1 ). According to the relative sensitivity of the nutlin-3-adapted sub-lines relative 218 to the respective parental cell lines, sub-lines were categorised as more sensitive (IC50 219 nutlin-3-adapted sub-line/ IC50 respective parental cell line <0.5), less sensitive (IC50 220 nutlin-3-adapted sub-line/ IC50 respective parental cell line >2), or similarly sensitive 221 (IC50 nutlin-3-adapted sub-line/ IC50 respective parental cell line >0.5 and <2) (Figure  222 6). 223
The sensitivity profiles indicated drug-and cell line-specific differences. Nutlin-224 3-resistance was not generally associated with increased resistance to other drugs 225 ( Figure 6 ). There was a noticeable heterogeneity in the drug response within the nutlin-226 3-resistant sub-lines of each parental cell line (Figure 1-4, 7) . This included the MV4-227 11 and OCI-AML-2 sub-lines, although nutlin-3 had selected pre-existing TP53-mutant 228 subpopulations in them. The maximum fold difference between nutlin-3-adapted sub-229 lines of the same parental cell line was 11.4 with MV4-11 r Nutlin 20µM XII having a 230 doxorubicin IC50 of 2.28ng/mL and MV4-11 r Nutlin 20µM VII having a doxorubicin IC50 of 231 26.0ng/mL (Figure 7) . 232
Finally, the drug response patterns were more similar between doxorubicin and 233 etoposide than between these two drugs and the other agents (Figure 1-4 [3, 35, 36, 39, 41] . A clinical trial in liposarcoma patients confirmed that MDM2 241 inhibitor therapy is also associated with the emergence of TP53 mutations in the clinic 242 Another one presented an R248W-mutant MV4-11 sub-line that had emerged during 252 prolonged cell line cultivation [9] . This suggests the consistent presence of an MV4-11 253 subpopulation that harbours an R248W TP53 mutation. 254
In contrast, the 12 nutlin-3-adapted OCI-AML-3 sub-lines included 9 TP53-255 mutant sub-lines, which all harboured different mutations, and 3 sub-lines that had 256 retained wild-type TP53. Similarly, the 8 SIG-M5 sub-lines consisted of 4 TP53-mutant 257 sub-lines, again each harbouring a different mutation, and 4 TP53 wild-type sub-lines.AML, cytotoxic chemotherapy selected pre-existing TP53-mutant clones that were 261 highly resistant to therapy [55, 56] . However, resistance formation to nutlin-3 was not 262 generally associated with cross-resistance to other anti-cancer drugs in AML cells. 263
Hence, loss-of-p53-function does not always seem to mediate resistance to cytotoxic 264 therapies directly. Indeed, RNAi-mediated depletion of p53 in SIG-M5 cells resulted in 265 increased resistance to nutlin-3 but not to doxorubicin (Suppl. Figure 1) . Notably, loss-266 of-p53 function may also indirectly increase the adaptability of AML cells to cytotoxic 267 anti-cancer therapies, for example due to increased genomic instability [54] . 
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The IC50 values are presented as they are and as fold changes (nutlin-3 IC50 nutlin-589 3-adapted sub-line/ nutlin-3 IC50 respective parental cell line). In addition, the 590 distribution of the nutlin-3 IC50 values is presented in the nutlin-3-adapted OCI-AML-591 3-and SIG-M5-sub-lines in dependence of their TP53 mutation status. Numerical data 592 are presented in Suppl. Table 1 . 593 594 
